Roche’s Immuno-Oncology Arsenal: PD-L1 And Beyond
This article was originally published in PharmAsia News
Roche may be playing catch-up to Bristol-Myers Squibb and Merck & Co in the PD-1/PD-L1 checkpoint development space, but it believes its unique in-house strengths in diagnostics and molecular biology, coupled with partnering, will enable it to play a major role in immuno-oncology.
You may also be interested in...
Roche may be behind Merck and Bristol in the PD-L1/PD-1 immune checkpoint inhibitor race, but its patient plans for atezolizumab are starting to demonstrate the power of the company's strategy of combining "comprehensive diagnostics" and a broad pipeline to establish a dominant position in immuno-oncology.
Roche gave updates on its immunotherapy research at ASCO, setting the stage for an ambitious slate of combination trials with the company's PD-L1 inhibitor atezolizumab.
After winning a major procurement contract, BeiGene now may need to find an alternative manufacturing site for Celgene's Abraxane to supply China.